PMID- 17803204
OWN - NLM
STAT- MEDLINE
DCOM- 20071031
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 30
IP  - 9
DP  - 2007 Sep
TI  - Does NT-proBNP remain a sensitive biomarker for chronic heart failure after 
      administration of a beta-blocker?
PG  - 469-74
AB  - BACKGROUND: Beta-blockers exert complex effects on plasma N-terminal-pro-B-type 
      natriuretic peptide (NT-proBNP) level. HYPOTHESIS: We aimed to investigate 
      whether NT-proBNP was still able to mirror the severity of chronic heart failure 
      and predict the prognosis of the disease after administration of a beta-blocker. 
      METHODS: Forty-four patients with chronic congestive heart failure were enrolled 
      in the study to randomly receive carvedilol or bisoprolol in addition to 
      background therapy. These patients underwent clinical measurement and blood 
      sampling for NT-proBNP measurement at baseline and 3 or 7 months after the 
      addition of the beta-blocker. The patients were followed-up for 3 years in order 
      to register the occurrence of all-cause death. RESULTS: NT-proBNP level showed a 
      positive correlation with the severity of heart failure as evaluated by New York 
      Heart Association (NYHA) classification both before and after administration of 
      either beta-blocker. The relationship between NT-proBNP and NYHA class was not 
      weakened with the duration of therapy. Furthermore, NT-proBNP was the only 
      independent predictor of all-cause mortality both before and after administration 
      of either beta-blocker. Left ventricular ejection fraction (LVEF), left 
      ventricular end diastolic diameter (LVEDD), age, NYHA class and treatment group 
      were not independently predictive of mortality in this study. CONCLUSIONS: The 
      ability of NT-proBNP to reflect the severity and to predict the endpoint in 
      chronic heart failure is not undermined after administration of a beta-blocker, 
      suggesting that NT-proBNP remains a sensitive biomarker for chronic heart failure 
      both before and after administration of a beta-blocker.
CI  - (c) 2007 Wiley Periodicals, Inc.
FAU - Li, Na
AU  - Li N
AD  - Clinical Pharmacology Center, Fu Wai Hospital, Chinese Academy of Medical 
      Sciences, Peking Union Medical College, Beijing, People's Republic of China.
FAU - Li, Yishi
AU  - Li Y
FAU - Wang, Fang
AU  - Wang F
FAU - Jiang, Wen
AU  - Jiang W
FAU - Huang, Jie
AU  - Huang J
FAU - Xu, Zhimin
AU  - Xu Z
FAU - Hua, Lu
AU  - Hua L
FAU - Hua, Congxiao
AU  - Hua C
FAU - Huang, Yan
AU  - Huang Y
FAU - Wu, Ying
AU  - Wu Y
FAU - Li, Feiou
AU  - Li F
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Biomarkers)
RN  - 0 (Carbazoles)
RN  - 0 (Peptide Fragments)
RN  - 0 (Propanolamines)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 0K47UL67F2 (Carvedilol)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - Y41JS2NL6U (Bisoprolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/administration & dosage/*therapeutic use
MH  - Biomarkers
MH  - Bisoprolol/administration & dosage/therapeutic use
MH  - Carbazoles/administration & dosage/therapeutic use
MH  - Carvedilol
MH  - Female
MH  - Heart Failure/blood/*diagnosis/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Propanolamines/administration & dosage/therapeutic use
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
PMC - PMC6653750
EDAT- 2007/09/07 09:00
MHDA- 2007/11/01 09:00
PMCR- 2007/09/05
CRDT- 2007/09/07 09:00
PHST- 2007/09/07 09:00 [pubmed]
PHST- 2007/11/01 09:00 [medline]
PHST- 2007/09/07 09:00 [entrez]
PHST- 2007/09/05 00:00 [pmc-release]
AID - CLC20150 [pii]
AID - 10.1002/clc.20150 [doi]
PST - ppublish
SO  - Clin Cardiol. 2007 Sep;30(9):469-74. doi: 10.1002/clc.20150.